Learn more about the proposed mechanism of action of epcoritamab (DuoBody-CD3xCD20).
Epcoritamab is a proprietary bispecific antibody created using Genmab's DuoBody® technology. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies. Epcoritamab is currently under investigation in a Phase I/II study for multiple hematological B-cell malignancies. Please note, Epcoritamab is an investigational compound and its safety and efficacy has not been established. For more information, please contact medinfo@genmab.com
Epcoritamab is a proprietary bispecific antibody created using Genmab's DuoBody® technology. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies. Epcoritamab is currently under investigation in a Phase I/II study for multiple hematological B-cell malignancies. Please note, Epcoritamab is an investigational compound and its safety and efficacy has not been established. For more information, please contact medinfo@genmab.com
